Incyte's ovarian-cancer plan shifts again before the trial begins.
Its last quarterly report had pointed to a new late-stage study. The latest filing drops that plan while leaving financial expectations unchanged.
Incyte has canceled the late-stage ovarian-cancer study it was preparing to start this quarter. The decision removes a trial from the very treatment setting the company had recently chosen to prioritize.
The planned MAESTRA-3 study would have tested its experimental drug INCB123667 with bevacizumab as first-line maintenance treatment. That means treatment intended to keep the cancer in check after initial therapy.
The earlier filing explains why the change matters
Research by Ticker Byline shows a second change in the program's direction across two recent filings. In its October 29 quarterly report, Incyte said it had stopped enrolling patients in MAESTRA-2 during the third quarter to focus on first-line maintenance treatment.
MAESTRA-2 was a Phase 3 study in patients whose ovarian cancer resists platinum-based chemotherapy. The report said the new MAESTRA-3 study, aimed at an earlier treatment setting, was planned to begin in the fourth quarter of 2026.
The November 13 filing cancels that planned launch. Investors following the program therefore face a different development path from the one laid out in the quarterly report just over two weeks earlier.
Management points to priorities, with financial targets unchanged
Incyte says it made the decision after reviewing priorities across its clinical-development portfolio. It says the cancellation was not based on safety or efficacy findings from the INCB123667 program.
That explanation matters: MAESTRA-3 had not begun. The announcement concerns the choice to commit resources to this particular trial, rather than results from it.
Incyte also says it does not expect the decision to affect its financial guidance or previously disclosed long-term outlook. It has not provided a revised budget or quantified savings from dropping the study.
The next question is where research resources go
Incyte sells medicines for blood disorders, cancer and skin conditions and earns royalties from partners. Its latest quarter generated $1.56 billion of revenue. Alongside that established business, its development choices determine which potential new treatments move toward larger trials.
The quarterly report described other programs, including the late-stage blood-disorder treatment acquired with Vega Therapeutics in July. Incyte has not linked the MAESTRA-3 decision to a specific replacement investment.
The next pipeline update can show what replaces the canceled milestone and where INCB123667 fits in the revised priorities. Our Incyte company profile keeps the trial history alongside the financial results and completed Vega acquisition.